Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Alles
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark Alles

Mark Alles

Board Member, Celgene

Crunchbase

Mark Alles's Career

Celgene
Celgene

Summit, NJ, US

Board Member· Board
BioMarin
BioMarin

San Rafael, CA, US

Board Member· Board
AI Proteins
AI Proteins

Boston, MA, US

Board Member· Board
Torl Biotherapeutics
Torl Biotherapeutics

Culver City, CA, US

CEO· C-Suite · Management
Wugen
Wugen

St. Louis, MO, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Alles's Career

Celgene
Celgene
Acquired01986Summit, NJ, US
Board Member· Board

Leadership at Celgene

Sol J. BarerSol J. BarerBoard Member
Robert HuginRobert HuginBoard Member
Robert HaririRobert HaririCo-Founder
Ernie MarioErnie MarioBoard Member
P Joseph CampisiP Joseph CampisiBoard Member
Jacqualyn FouseJacqualyn FouseBoard Member
BioMarin
BioMarin
Public$585.8M3.1k1997San Rafael, CA, US
Board Member· Board

Leadership at BioMarin

Liz McKee AndersonLiz McKee AndersonBoard Member
David PyottDavid PyottBoard Member
Willard DereWillard DereBoard Member
Randy MeierRandy MeierBoard Member
Alexander HardyAlexander HardyCEO
Christopher M. StarrChristopher M. StarrCo-Founder

Similar to BioMarin

BioCryst PharmaceuticalsBioCryst PharmaceuticalsDurham, NC, USPharmaceuticalsest. 1986BioCryst PharmaceuticalsDurham, NC, US · est. 1986

BioCryst Pharmaceuticals: A global biotech firm innovating oral treatments for rare diseases.

Public · $1.8B531
Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
AI Proteins
AI Proteins
Series B$18.2M442021Boston, MA, US
Board Member· Board

Leadership at AI Proteins

Chris BahlChris BahlCo-Founder
Marc CohenMarc CohenCo-Founder
Noah D. BeermanNoah D. BeermanCEO
Carl NovinaCarl NovinaCo-Founder
Torl Biotherapeutics
Torl Biotherapeutics
Series B$158M182018Culver City, CA, US
CEO· C-Suite · Management
Wugen
Wugen
Series B$172M892018St. Louis, MO, US
Board Member· Board

Leadership at Wugen

Bali MuralidharBali MuralidharBoard Member
Melissa Berrien-ElliottMelissa Berrien-ElliottFounder
Bosun HauBosun HauBoard Member
Kumar SrinivasanKumar SrinivasanCEO

Similar to Wugen

Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Catamaran BioCatamaran BioBoston, MA, USCell Therapiesest. 2020Catamaran BioBoston, MA, US · est. 2020

Catamaran Bio, a biotech firm, innovates in allogeneic immune cell therapies, specializing in CAR-NK cell therapies.

Series A · $42M41
Modulus TherapeuticsModulus TherapeuticsSeattle, WA, USCell Therapies, Therapeuticsest. 2020Modulus TherapeuticsSeattle, WA, US · est. 2020

Modulus: Engineering advanced immune cell therapies for solid tumor treatment.

Seed · $3.5M15
Avenge BioAvenge BioNatick, MA, USImmunotherapiesest. 2019Avenge BioNatick, MA, US · est. 2019

Avenge Bio: Developing transformative therapeutics to potentially eradicate solid tumors.

Series A · $45M23

Mark Alles's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Mark Alles

Michael MorrisMichael MorrisBoard Member · TorcMark WilsonMark WilsonFounder & CEO · TL BiolabsFaisal AlmaklasFaisal AlmaklasFounder · TorodCourtney WilliamsCourtney WilliamsBoard Member · Johns Hopkins UniversityJames RogersJames RogersCo-Founder & CEO · RealReportsGerald ReaGerald ReaCEO · Toralgen